Information Provided By: 
Fly News Breaks for July 29, 2019
DXR
Jul 29, 2019 | 09:24 EDT
As previously reported, Maxim analyst Anthony Vendetti initiated Daxor with a Buy rating and a price target of $22. The analyst cites the company's "substantial commercial opportunity" with blood volume analysis device that may alter the standard of care in providing an accurate and quick measure of blood volume in helping diagnose ailments such as heart and kidney failure and hypertension.
News For DXR From the Last 2 Days
There are no results for your query DXR
